Physician profile
Sara Cha
NPI 1568218550
$2,641.99
in general payments reported to CMS, 2019-2025
10 companies · $1,839 in 2025
The $1,839 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $803 · 2025: $1,839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,641.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $706.37 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Harrow Eye, LLC | $502.70 | 2024-2025 | Vevye |
| Alcon Vision LLC | $425.27 | 2024-2025 | Rocklatan, Tryptyr, Rhopressa |
| Dompe US, INC. | $337.96 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $201.16 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $151.53 | 2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $110.92 | 2025 | |
| Coopervision INC. | $100.00 | 2025 | Clariti Contact Lens |
| Rxsight INC | $57.54 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Abbvie INC. | $48.54 | 2024-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Cha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.